Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout

byiShook Opinion
Sep 26, 2024 - 21:15

Share

Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday. The post Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout appeared first on Investor's Business Daily.

Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday.

The post Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout appeared first on Investor's Business Daily.